Literature DB >> 14556259

Effector HIV-specific cytotoxic T-lymphocyte activity in long-term nonprogressors: associations with viral replication and progression.

Elizabeth Keoshkerian1, Lesley J Ashton, Danielle G Smith, John B Ziegler, John M Kaldor, David A Cooper, Graeme J Stewart, Rosemary A Ffrench.   

Abstract

Ex vivo effector cytotoxic T-lymphocyte (CTL) activity was assessed in 27 members of the Australian Long-Term Nonprogressor cohort and correlated with genetic, virological, and immunological markers. The 27 individuals were antiretroviral naive with CD4(+) T-cell counts of >500 cells/ microl for more than 8 years after human immunodeficiency virus type 1 (HIV-1) infection. Effector CTL activity was determined using a standard ex vivo chromium release assay. Individuals with CTL activity (HIV-1 env(IIIB) or pol or gag) were then compared to those without CTL activity in relation to plasma HIV-1 RNA, ICD p24 antigen, beta(2)-microglobulin, CD4 and CD8 T-cell counts, CCR5 and CCR2b genotypes, and progression to CD4 <500 cells/microl or commencement of antiretroviral treatment. Of the 27 individuals examined, 19 had no detectable effector CTL activity. The eight individuals with detectable CTL activity had significantly higher plasma levels of HIV-1 RNA (P = 0.014), immune complex dissociated p24 antigen (P = 0.006), and beta(2)-microglobulin (P = 0.009). There was increased risk of progression within 4 years of study entry in individuals with detectable effector CTL activity, higher plasma levels of HIV-1 RNA, higher beta(2)-microglobulin levels, and higher immune complex dissociated p24 antigen levels at enrollment (P = 0.017, P = 0.004, P = 0.027, P = 0.008 respectively). Multivariate analysis demonstrated viral load remained the strongest predictor of disease progression within this group (P = 0.017). There were no significant associations between CTL response and chemokine receptor genotype. These findings demonstrate the importance of HIV replication in generating an effector CTL response and show that effector CTL activity may be an early predictor of progression in people with long-term asymptomatic HIV infection. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14556259     DOI: 10.1002/jmv.10525

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

1.  Alterations of natural killer cell and T-lymphocyte counts in adults infected with human immunodeficiency virus through blood and plasma sold in the past in China and in whom infection has progressed slowly over a long period.

Authors:  Yongjun Jiang; Hong Shang; Zining Zhang; Yingying Diao; Di Dai; Wenqing Geng; Min Zhang; Xiaoxu Han; Yanan Wang; Jing Liu
Journal:  Clin Diagn Lab Immunol       Date:  2005-11

2.  Sequential broadening of CTL responses in early HIV-1 infection is associated with viral escape.

Authors:  Annika C Karlsson; Astrid K N Iversen; Joan M Chapman; Tulio de Oliviera; Gerald Spotts; Andrew J McMichael; Miles P Davenport; Frederick M Hecht; Douglas F Nixon
Journal:  PLoS One       Date:  2007-02-21       Impact factor: 3.240

3.  Predictors of disease progression in HIV infection: a review.

Authors:  Simone E Langford; Jintanat Ananworanich; David A Cooper
Journal:  AIDS Res Ther       Date:  2007-05-14       Impact factor: 2.250

4.  Long term non-progressor (LTNP) HIV infection.

Authors:  Praveen Kumar
Journal:  Indian J Med Res       Date:  2013-09       Impact factor: 2.375

5.  Elevated CD8 T-cell counts and virological failure in HIV-infected patients after combination antiretroviral therapy.

Authors:  Nam Su Ku; Awachana Jiamsakul; Oon Tek Ng; Evy Yunihastuti; Do Duy Cuong; Man Po Lee; Benedict Lim Heng Sim; Praphan Phanuphak; Wing-Wai Wong; Adeeba Kamarulzaman; Fujie Zhang; Sanjay Pujari; Romanee Chaiwarith; Shinichi Oka; Mahiran Mustafa; Nagalingeswaran Kumarasamy; Kinh Van Nguyen; Rossana Ditangco; Sasisopin Kiertiburanakul; Tuti Parwati Merati; Nicolas Durier; Jun Yong Choi
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.